



Azoles susceptibility profiles of more than 9,000 clinical yeast isolates belonging to 40 common and rare species

Marie Desnos-Ollivier, Olivier Lortholary, Stéphane Bretagne, Françoise Dromer, The French Mycoses Study Group

► To cite this version:

Marie Desnos-Ollivier, Olivier Lortholary, Stéphane Bretagne, Françoise Dromer, The French Mycoses Study Group. Azoles susceptibility profiles of more than 9,000 clinical yeast isolates belonging to 40 common and rare species. *Antimicrobial Agents and Chemotherapy*, 2021, 10.1128/AAC.02615-20 . pasteur-03197059

HAL Id: pasteur-03197059

<https://pasteur.hal.science/pasteur-03197059>

Submitted on 13 Apr 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Azoles susceptibility profiles of more than 9,000 clinical yeast isolates belonging to 40 common and rare species

Running title : Azoles distribution of 40 common & rare yeast species

Marie Desnos-Ollivier^{1*}, Olivier Lortholary^{1,2,3}, Stéphane Bretagne^{1,3,4}, Françoise Dromer¹ on behalf of the French Mycoses Study Group[^]

Affiliation

¹ Institut Pasteur, CNRS, Molecular Mycology Unit, National Reference Center for Invasive Mycoses & Antifungals, UMR2000, Paris, France.

² Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants malades, APHP, IHU Imagine, Paris, France.

³ Université de Paris, France.

⁴ Université Paris Diderot, Laboratoire de Parasitologie-Mycologie, Hôpital Saint Louis, AP-HP, Paris, France.

***Corresponding author**

Marie Desnos Ollivier

mdesnos@pasteur.fr

[^]Members of the French Mycoses Study Group are listed in the Acknowledgments section.

Abstract

Invasive yeast infections represent a major global public health issue and only few antifungal agents are available. Azoles are one of the classes of antifungals used for treatment of invasive candidiasis. The determination of antifungal susceptibility profiles using

standardized methods is important to identify resistant isolates and to uncover the potential emergence of intrinsically-resistant species. We here report data on 9,319 clinical isolates belonging to 40 pathogenic yeast species recovered in France over 17 years. The antifungal susceptibility profiles were all determined at the National Reference Center for Invasive Mycoses and Antifungals based on the EUCAST broth microdilution method. The centralized collection and analysis allowed us to describe the trends of azoles susceptibility of isolates belonging to common species, confirming the high susceptibility for *C. albicans* (n=3,295), *C. tropicalis* (n=641), *C. parapsilosis* (n=820), and decreased susceptibility for *C. glabrata* (n=1,274), and *P. kudriavzevii* (n=343). They also provide interesting data concerning azole susceptibility of *Cr. neoformans* species complex: showing comparable MICs distribution for the three species but lower MIC50 and MIC90 for serotype D (n=208) compared to serotype A (n=949) and AD hybrids (n=177). Finally, these data provide useful information for rare and/or emerging species such as *C. lusitaniae* (n=221), *S. clavata* (n=184), *M. guilliermondii* complex (n=150), *C. haemulonii* complex (n=87), *R. mucilaginosa* (n=55), *W. anomalus* (n=36).

Introduction

Invasive fungal infections (IFIs) represent a major worldwide public health issue with an incidence of 5.9 to 20.3 cases/100 000 patients per year in France, up to 27.2 / 100 000 in USA and 14.1/100 000 in the United Kingdom (1-5). Despite treatment, the mortality remains high, ranging from 7.5 to 27.6%, with an estimation of 1.5 million deaths annually (6). Yeasts are the main causative agents of these infections and only few antifungals are effective against the most common Ascomycetous yeasts, and even less against Basidiomycetous yeasts. The azoles are the largest class of antifungal agents used for treatment of IFIs, especially fluconazole for treatment of candidemia (7, 8). Azoles inhibit the 14-alpha-lanosterol

demethylase (Cyp51), resulting in depletion of ergosterol synthesis, a major component of the fungal cell wall and in accumulation of toxic 14- α -demethylated sterols in the membrane (9). The determination of *in vitro* antifungal susceptibility allows determination of wild type population and those with acquired or mutational resistance to the drug. Therefore, epidemiological surveys and standardized methods of antifungal susceptibility testing are important to confirm or not that the antifungal susceptibility of a given species remains unchanged/stable. Among internationally recognized standards, two broth microdilution methods are well standardized by the EUCAST (European Committee on Antimicrobial Susceptibility Testing) and the CLSI (Clinical and Laboratory Standards Institute) for determining minimal inhibitory concentrations (MICs). Expert committees in both instances establish breakpoints (BPs) and epidemiological cut-off (abbreviated ECOFFs for EUCAST, and ECVs for CLSI) values in order to easily distinguish between susceptible and resistant and wild-type and non-wild-type isolates, respectively. BPs are defined for a limited number of species and antifungal agents based on MICs distributions, clinical data, pharmacodynamics and pharmacokinetics of the drugs while ECOFFs are determined based only on MICs distributions. An ECOFF corresponds to the MIC that separates a population of isolates into wild-type and non-wild type. Unlike BP, ECOFF does not necessarily predict clinical failure but it can be helpful for clinical decision (SOP10.1 <https://eucast.org/documents/sops/> (10)). The EUCAST Antifungal Susceptibility Testing subcommittee (EUCAST-AFST) regularly updates data concerning MICs distributions, and ECOFFs for frequent species involved in human infections based on data generated by more than 15 European centers (<http://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals/>, (11)). Furthermore, all over the world, mono- or multicentric studies provide reports adding to the knowledge on antifungal susceptibility profiles, mostly of common yeast species (12-20). For rare species

however, obtaining robust data is difficult given the low number of reported cases (12). Centralized data are therefore important for these species to determine their normal susceptibility profile (10).

The French National Reference Center for Invasive Fungal Infections and Antifungals (NRCMA) provides antifungal susceptibility testing results using the EUCAST method for all the isolates collected through its missions of expertise on pathogenic fungi and surveillance of IFIs in France. We here report the results obtained for azoles on more than 9,000 clinical isolates belonging to 40 different species, collected nationwide in France between 2003 and 2019. These data provide an overview of the susceptibility to azoles of frequent and rare pathogenic yeast species in France.

Results

A total of 9,319 yeast isolates were included in the analysis. These isolates, received at the NRCMA between the 1st of September 2003 and the 31st December of 2019, were mainly involved in IFIs (80.8%; 6,853 recovered from blood cultures, and 679 from cerebrospinal fluids or brain abscesses cultures). The isolates belonged to 40 different species (32/40 were Ascomycetes corresponding to 17 genera, and 8/40 were Basidiomycetes belonging to 4 genera). Eleven species were represented by more than 100 isolates: *Candida albicans*, *Candida glabrata*, *Candida tropicalis*, *Candida parapsilosis* and *Pichia kudriavzevii* (syn. *Candida krusei*) and *Cryptococcus neoformans* complex followed by *Clavispora lusitaniae*, *Kluyveromyces marxianus*, *Saprochaete clavata*, *Candida dubliniensis* and *Meyerozyma guilliermondii* (Table 1). Ranges of MICs, MIC50 and MIC90 for fluconazole, voriconazole and posaconazole are listed in Table 1 while MICs distributions are presented in Table S1. Of note, while the median MIC values for each batch of QC strains (ATCC22019 and ATCC6258) were always in the range of acceptable MIC defined by EUCAST-AFST for

fluconazole and voriconazole, they were one dilution higher for posaconazole between 2011 and 2015. However, the proportion of posaconazole-resistant ($\text{MIC} > 0.06 \text{ mg/L}$) isolates was not higher at that time (Figure 1).

We first compared the MIC distributions recorded at the NRCMA to those available in the EUCAST dataset. For fluconazole and voriconazole, ranges of MICs were similar or with a maximum variation of 2 dilutions. Medians of MICs were equal or with a maximum of one dilution difference for *C. albicans*, *C. dubliniensis*, *C. glabrata*, *C. parapsilosis*, *C. tropicalis*, *P. kudriavzevii*, *W. anomalus*, *K. marxianus*, *C. lusitaniae* and *M. guilliermondii* (data not shown). For posaconazole, MIC distributions were also similar except for *C. parapsilosis*, *C. tropicalis* and *M. guilliermondii* (Supplemental Figure 1) with a median MIC value for the NRCMA dataset 2 dilutions higher than for the EUCAST dataset.

Among the *Candida parapsilosis* complex, the three species had similar MIC distribution for posaconazole while *C. metapsilosis* isolates had lower MICs for voriconazole and fluconazole but a higher MIC₅₀ for fluconazole than *C. parapsilosis* and *C. orthopsilosis*. Using EUCAST BP for fluconazole ($\text{R} > 4 \text{ mg/L}$), *C. orthopsilosis* has the highest number of resistant isolates (12.2%) (Table 1, Figure 2).

For *Cr. neoformans*, range of MICs, MIC₅₀ and MIC₉₀ were determined for serotype A, serotype D and AD hybrids. The distribution of MICs was comparable for the three species but for the three azoles, serotype D isolates exhibited lower MIC₅₀ and MIC₉₀ than serotypes A and AD hybrids (Table 1 and Table S1).

Using the EUCAST breakpoints (BP) for fluconazole, 32.4% *C. glabrata* isolates were resistant ($\text{R} > 16 \text{ mg/L}$) compared to less than 7.5% of the isolates for all the other common species ($\text{R} > 4 \text{ mg/L}$) (Table 1). Using the non-species related BP defined by EUCAST for fluconazole ($\text{R} > 4 \text{ mg/L}$), four species (*C. haemulonii*, *C. duobushaemulonii*, *C.*

palmiophila, *C. auris*) had more than 90% of resistant isolates while three others (*C. metapsilosis*, *C. orthopsilosis* and *C. nivariensis*) had 2.2%, 12.2% and 7.7% of fluconazole-resistant isolates, respectively. According to the BPs for posaconazole (R>0.25 mg/L) and voriconazole (R>0.06 mg/L), the percentage of resistant isolates was 23.9% and 2.2% for *C. parapsilosis* and 27.3% and 9.5% for *C. tropicalis*, respectively (Table 1).

According to the EUCAST ECOFF, 26.8% of *P. kudriavzevii* (ECOFF=128mg/L) and 20% of *M. guilliermondii* (ECOFF=16mg/L) isolates were considered as non-wild type for fluconazole. Likewise, 9.6% of *C. glabrata* (ECOFF=1mg/L), 4.5% of *C. lusitaniae* (ECOFF=0.06mg/L), 13.9% of *M. guilliermondii* (ECOFF=0.25mg/L) and 2.6% of *P. kudriavzevii* (ECOFF=1mg/L) isolates were considered as non-wild type for voriconazole (Table 1).

Among the population of *C. glabrata* isolates, 7.9 % (101/1274) were simultaneously resistant to fluconazole and considered non-wild-type for voriconazole. Among the 155 *C. albicans* isolates resistant to at least one azole, 49 (31.6%) were resistant to the three azoles. Cross-resistance to the three azoles concerned 0/8 *C. dubliniensis*, 29/192 (15.1%) *C. tropicalis*, and 7/236 (3.0%) *C. parapsilosis* (Supplemental Figure 2). The majority (>80%) of isolates resistant to at least one azole were resistant to posaconazole. The proportion of posaconazole-resistant isolates varied according to the year of isolation for *C. tropicalis* and *C. parapsilosis* (Figure 1). This variation was correlated with variation of voriconazole-resistance for *C. tropicalis*.

Discussion

In the present study, we report the azoles susceptibility profiles for 40 yeast species involved in IFIs based on the MIC distribution of 9,319 clinical isolates recovered in France between 2003 and 2019. We provide azole profiles for common, emerging and rare species thanks to

our varied and important collection of isolates. Our results confirm that *C. albicans*, *C. dubliniensis*, *C. tropicalis*, *C. parapsilosis* complex, *K. marxianus* and *C. lusitaniae* can be considered as susceptible *in vitro* to fluconazole, voriconazole and posaconazole (14, 16, 18, 19, 21), while (i) *C. neoformans* complex has decreased *in vitro* susceptibility to fluconazole, (ii) *P. kudriavzevii* and uncommon species *C. haemulonii* complex, *M. guilliermondii* complex, *P. norvegensis*, *S. clavata*, *G. candidus* and *R. mucilaginosa* can be considered as intrinsically resistant to fluconazole ($\text{MIC}_{90} \geq 64\text{mg/L}$) (17, 19, 20, 22-24). Of note, *C. haemulonii* and *C. duobushaemulonii*, which belong to the same species complex and are closely related to the emerging *C. auris*, can also be considered intrinsically resistant to voriconazole and posaconazole (19, 25, 26). Other uncommon species such as *S. cerevisiae*, *K. ohmeri*, *C. palmiophila*, *P. cactophila*, *M. capitatus*, *Y. lipolytica*, *Cr. gattii* and *T. asahii* should be considered as less susceptible *in vitro* to fluconazole, with “intermediate” MIC value ($\text{MIC}_{90} \geq 16\text{mg/L}$) (27, 28) while voriconazole seems to be the most potent azole *in vitro*, which is already known for *Trichosporon* spp. (7, 23). When considering the *C. parapsilosis* complex, *C. metapsilosis* was the species the most sensitive *in vitro* to azoles with the lowest percentage of fluconazole-resistant isolates while *C. orthopsilosis* seemed to be more resistant than the other species of the complex with the highest percentage of fluconazole-resistant isolates and the highest MIC₉₀ for fluconazole, voriconazole and posaconazole (12, 19). There may be a link between the low frequency of *C. metapsilosis* recovered from IFIs in the literature (29) and this highest azole sensitivity. Another hypothesis proposed by Gago *et al.* is that *C. metapsilosis* has a reduced ability to produce some of the known virulence factors (30). Finally, we confirmed that very rare species *L. elongisporus* and *Cy. fabianii* were susceptible to the three azoles while *W. anomalus*, *K. ohmeri* and *Cy. jadinii* were less susceptible to fluconazole with “intermediate” MICs (12, 31-38).

Despite reports of azole resistance acquired after treatment, in common and rare yeast species, and description of an increasing percentage of resistant isolates (39), this phenomenon remains rare (1, 16, 40, 41) or has geographical specificity (42, 43), and seems to concern especially *C. tropicalis*, *C. glabrata* and *C. parapsilosis* (17). In the present study, we observed a proportion of fluconazole-resistant isolates among *C. albicans* and *C. parapsilosis* isolates similar to that reported in international surveys (17, 19, 20, 28, 44). We observed posaconazole-resistant isolates of *C. tropicalis* and *C. parapsilosis* complex (23.9 and 27.3%, respectively), with a variable proportion, according to the year of isolation. The increased proportion of posaconazole-resistant *C. tropicalis* isolates correlated with an increased proportion of voriconazole-resistance of those isolates. This heterogeneous percentage of resistant isolates in our collection remained unexplained. Indeed, we raised a few hypotheses: (i) Technical issues related to the batch of antifungal powder or RPMI medium that translated into a higher median posaconazole and not the other azoles MIC for the QC strains, but this was not associated with an increase in the proportion of posaconazole-resistant isolates in the related series; (ii) Geographic specificity and/or local outbreak could be responsible as described for instance in the multicentric CHIF-Net study (19) and in a national survey in Belgium (43), but none was reported to our knowledge; (iii) Bias related to the isolates analyzed knowing that 22% of the isolates were sent for expertise following therapeutic failure and not part of the epidemiological surveys (2, 45). However, posaconazole-resistance was not restricted to the isolates sent for expertise.

We also report an important percentage of *C. glabrata* isolates resistant to fluconazole (32.4%). The proportion of *C. glabrata* resistant to fluconazole seems to be very heterogeneous according to the country, the center and the year of isolation. In fact, Xiao *et al.* reported 10.3 to 19% of resistant isolates in China between 2009-2017 (19, 20, 23), based on the CHIF-Net study, while Pfaller *et al.* published 0 to 28.6%, according to the year of

isolation in the SENTRY study (44), Bassetti *et al.*, reported a percentage of 0 to 21.2% in the SENTRY and ARTEMIS studies depending on the continent (46), Borman *et al.* and Trouvé *et al.* reported 12.7% and 11.3% of resistance, respectively in national studies (28, 43). Of note, the BP values for *C. glabrata* was modified by EUCAST-AFST committee in 2020, from R>32mg/L to R>16mg/L (11). When using the previous BP (MIC>32mg/L), 18.8% of *C. glabrata* in our collection was identified as resistant to fluconazole, which is comparable to the studies published earlier before the change of the BP threshold.

Our data confirm azole susceptibility profiles for frequent species and, to our knowledge, it is one of the only studies to assemble MIC data for more than 40 pathogenic yeast species, mainly involved in invasive infection, including big samples of isolates, even for rare and emerging species such as *C. lusitaniae* (n=221), *S. clavata* (n=184), *M. guilliermondii* complex (n=150), *C. haemulonii* complex (n=87), *R. mucilaginosa* (n=55), *W. anomalus* (n=36) (12). This emphasizes the importance of centralization of isolates for collection and analysis by National Reference Centers. Our results confirm that an antifungal susceptibility profile is associated with each species, hence the importance of accurate yeast species identification as soon as possible to infer the susceptibility profile. Of course, it goes without saying that the determination of MICs, using standardized methods, remains important for rare species and the monitoring of potential emergence of resistance including in the context of therapeutic failure.

Materials & Methods

Isolates

Between the 1st January of 2003 and the 31st December of 2019, a total of 9,449 yeast were sent to the National Reference Center for Mycosis & Antifungal agents (NRCMA). We

analyzed MICs data for 9,319 isolates belonging to the species for which at least 5 isolates were available. Majority of the isolates were sent for expertise (7358/9,319; 78.8%; i.e. species identification, antifungal susceptibility testing) and/or as participation to epidemiological surveys. For rare species represented by 10 or less isolates, all isolates were recovered from different patients.

Species identification

For all isolates, purity was checked on chromogenic medium (BBL™ Chromagar™ Candida Medium, BD, GmbH) or Niger seed agar for *Cryptococcus* spp.. Phenotypic identification was performed using carbon assimilation profiles (ID32C, BioMérieux, Marcy-l'Etoile, France) before 2014, and matrix assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF, MALDI Biotyper, Bruker Daltonik, GmbH) since 2014. Duplex PCR was performed to differentiate *Candida dubliniensis* and *Candida albicans* (47). For all isolates, PCR and sequencing of ITS1-5.8S-ITS2 and D1D2 regions were performed, except for *C. glabrata*, *C. tropicalis*, *P.kudriavzevii* and *K. marxianus*, using V9D/LS266 (48, 49) and NL1/NL4 (50) primers, respectively. In addition, part of the actin gene (for *C. lusitaniae* (51) and *Debaryomyces* species (52)), part of the RPBI gene (for *M. guilliermondii*, *M. caribbica*, *C. carpophila* (53)) or the IGS1 region (for *Trichosporon* species (54)) were sequenced. Sequences were compared to sequences of the type strain of each species and of the closely related species. Serotype was determined for *Cr. neoformans* isolates by PCR amplification of part of GPA1 and PAK1 genes using a triplex PCR with primers specific of the serotype previously described (55).

Antifungal susceptibility

Minimal inhibitory concentrations (MICs) were determined for all isolates, for 3 antifungal agents (fluconazole provided by Pfizer Inc (NewYork, USA), Sigma-Aldrich (Merck KGaA,

Darmstadt, Germany) and Alsachim (Shimadzu Group Company, France); voriconazole provided by Pfizer and Alsachim and posaconazole provided by SheringPlough (Merck & Co. Inc., USA) and Alsachim) by using the standardized broth microdilution method EUCAST following the procedure E. DEF 7.3.2 (https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7.3.2_Yeast_testing_definitive_revised_2020.pdf), in 96 plate (sterile Tissue culture plates, 96 well flat bottom in clear polystyrene, TPP® Techno Plastic Products AG, Switzerland, Reference 92096). The concentrations tested ranged between 0.0015 mg/L to 8 mg/L for posaconazole and voriconazole and between 0.125 mg/L to 64 mg/L for fluconazole. QC strains (ATCC22019, ATCC6258) were included in each set. The concentrations corresponding to the MIC that inhibited 50% (MIC50) and 90% (MIC90) of the isolates were determined for species having 10 or more isolates.

Our dataset (MIC distribution) was compared with that available on the EUCAST website (<https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=init>, June 2020).

The BP or ECOFF values determined by EUCAST for some species and some antifungal agents (https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoint_s/AFST_BP_v10.0_200204.pdf) were used to calculate percentage of resistant (R) isolates and non-wild-type (NWT), respectively. Non-species related BP for fluconazole, defined by EUCAST, (MIC >16 mg/L) for *Candida* were also used to calculate percentage of resistant isolate for *C. orthopsilosis*, *C. metapsilosis*, *C. nivariensis*, *C. haemulonii*, *C. duobushaemulonii* and *C. palmioleophila*. Since not all isolates were collected through unbiased epidemiological survey (7358/9,319; 78.8%), we did not determine local ECOFF, and reported only the percentage of resistant or non-wild-type isolates in our collection.

Acknowledgments

Members of the French Mycoses Study group who contributed to the data are in alphabetical order of the cities, all the French microbiologists and mycologists who sent isolates for characterization of unusual antifungal susceptibility profiles or to contribute to the ongoing surveillance program on the epidemiology of invasive fungal infections in France (YEASTS and RESSIF programs): N. Brieu (CH Aix); T. Chouaki, C. Damiani, A. Totet (CHU Amiens; J. P. Bouchara, M. Pihet (CHU Angers); S. Bland (CH Annecy); V. Blanc (CH Antibes); S. Branger (CH Avignon); A. P. Bellanger, L. Million (CHU Besançon); C. Plassart (CH Beauvais); I. Poilane (hôpital Jean Verdier, Bondy); I. Accoceberry, L. Delhaes, F. Gabriel (CH Bordeaux); A. L. Roux, V. Sivadon-Tardy (hôpital Ambroise Paré, Boulogne Billancourt); F. Laurent (CH, Bourg en Bresse); S. Legal, E. Moalic, G. Nevez, D. Quinio (CHU Brest); M. Cariou (CH Bretagne Sud); J. Bonhomme (CHU, Caen); B. Podac (CH, Chalon sur Saône); S. Lechatch (CH, Charleville-Mézières); C. Soler (hopital d'Instruction des armées, Clamart); P. Poirier, C. Nourrisson (CHU, Clermont Ferrand); O. Augereau (CH, Colmar); N. Fauchet (CHIC, Créteil); F. Dalles (CHU, Dijon); P. Cahen (CMC, Foch); N. Desbois, C. Miossec (CHU, Fort de France); J. L. Hermann (hôpital Raymond Poincaré, Garches); M. Cornet, D. Maubon, H. Pelloux (CHU, Grenoble); M. Nicolas (CHU, Guadeloupe); C. Aznar, D. Blanchet, J. F. Carod, M. Demar, (CHU, Guyane); A. Angoulvant (hôpital Bicêtre, le Kremlin Bicêtre); C. Ciupek (CH, Le Mans); A. Gigandon (hôpital Marie Lannelongue, Le Plessis Robinson); B. Bouteille (CH Limoges); E. Frealle, B. Sendid (CHU Lille); D. Dupont, J. Menotti, F. Persat, M. Wallon (CHU, Lyon); C. Cassagne, S. Ranque (CHU, Marseille); T. Benoit-Cattin, L. Collet (CH Mayotte); A. Fiacre (CH Meaux); N. Bourgeois, L. Lachaud (CHU, Montpellier); M. Machouart (CHU, Nancy); P. Lepape, F. Morio (CHU, Nantes); O. Moquet (CH, Nevers); S. Lefrançois (hôpital Américain, Neuilly); M. Sasso (CHU, Nimes); F. Reibel (GH, Nord-Essone); M. Gari-Toussaint, L.

297 Hasseine (CHU Nice) ; L. Bret, D. Poisson (CHR Orléans) ; S. Brun (hôpital Avicenne,
 298 Paris) ; C. Bonnal, S. Houze (hôpital Bichat, Paris) ; A. Paugam (hôpital Cochin, Paris) ; E.
 299 Dannaoui (HEGP, Paris) ; N. Ait-Ammar, F. Botterel, R. Chouk (CHU Henri Mondor, Paris),
 300 M. E. Bougnoux, E. Sitterle (hôpital Necker, Paris), A. Fekkar, R. Piarroux (hôpital Pitié
 301 Salpêtrière, Paris); J. Guitard, C. Hennequin (hôpital St Antoine, Paris) ; M. Gits-Muselli, S.
 302 Hamane (hôpital Saint Louis, Paris) ; S. Bonacorsi, P. Mariani (hôpital Robert Debré, Paris) ;
 303 D. Moissenet (hôpital Trousseau, Paris) ; A. Minoza, E. Perraud, M. H. Rodier (CHU
 304 Poitiers) ; G. Colonna (CH, Porto Vecchio) ; D. Toubas (CHU Reims), J. P. Gangneux, F.
 305 Robert-Gangneux (CHU Rennes); O. Belmonte, G. Hoarau, M. C. Jaffar Bandjee, J. Jaubert,
 306 S. Picot, N. Traversier (CHU Réunion); L. Favennec, G. Gargala (CHU, Rouen) ; C. Tournus
 307 (CH, St Denis) ; H. Raberin (CHU, St Etienne) ; V. Letscher Bru (CHU, Strasbourg) ; S.
 308 Cassaing (CHU, Toulouse) ; P. Patoz (CH Tourcoing); E. Bailly, G. Desoubieux (CHU
 309 Tours) ; F. Moreau (CH Troyes) ; P. Munier (CH Valence) ; E. Mazars (CH Valenciennes) ;
 310 O. Eloy (CH Versailles) ; E. Chachaty (Institut Gustave Roussy, Villejuif) ; and members of
 311 the NRCMA (Institut Pasteur, Paris): A. Boullié, C. Gautier, V. Geolier, C. Blanc, D. Hoinard
 312 and D. Raoux-Barbot for technical help, and K. Boukris-Sitbon, F. Lanternier, A. Alanio, D.
 313 Garcia-Hermoso for their expertise and contribution to the surveillance programs.

314

315 **Funding**

316 Institut Pasteur and Santé Publique France.

317

318 **Figure Legends**

319 **Figure 1. Percentage of fluconazole, voriconazole and posaconazole -resistant isolates,**
 320 **according to the year of isolation, for (A) *Candida albicans*.** The proportion of resistant
 321 isolates being similar for posaconazole and fluconazole between 2016 and 2019, the lines are

overlaid; (B) *Candida parapsilosis*, and (C) *Candida tropicalis* (voriconazole and fluconazole lines overlaid between 2015 and 2019).

Figure 2. MIC distribution of *Candida parapsilosis* complex isolates for (A) Voriconazole, (B) Fluconazole and (C) Posaconazole. EUCAST breakpoint values (R) for *C. parapsilosis sensu stricto* are indicated in the graphs.

Supplemental Figure 1. Comparison of EUCAST and CNRMA data for posaconazole MIC distribution of *C. tropicalis* (A), *C. parapsilosis* (B) and *M. guilliermondii*. EUCAST breakpoint value (R) or ECOFF value are indicated in the graphs.

Supplemental Figure 2. Azoles cross-resistance. Graphs represent the number of isolates resistant for each azoles, for two or three azoles among isolates resistant for at least one azoles for (A) *Candida albicans*, (B) *Candida dubliniensis*, (C) *Candida tropicalis* and (D) *Candida parapsilosis*

References

1. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, Fontanet A, Bretagne S, Dromer F, French Mycosis Study G. 2014. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). *Intensive Care Med* 40:1303-12.
2. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F. 2014. Population-based analysis of invasive fungal infections, France, 2001-2010. *Emerg Infect Dis* 20:1149-55.

3. Gangneux JP, Bougnoux ME, Hennequin C, Godet C, Chandenier J, Denning DW, Dupont B, Life program tSfdmmS-sg. 2016. An estimation of burden of serious fungal infections in France. *J Mycol Med* 26:385-390.
4. Pegorie M, Denning DW, Welfare W. 2017. Estimating the burden of invasive and serious fungal disease in the United Kingdom. *J Infect* 74:60-71.
5. Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. 2018. Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. *Open Forum Infect Dis* 5:ofy187.
6. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. *Sci Transl Med* 4:165rv13.
7. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, European Society of Clinical M, Infectious Diseases Fungal Infection Study G, European Confederation of Medical M. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. *Clin Microbiol Infect* 20 Suppl 3:76-98.
8. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 62:e1-50.
9. Bhattacharya S, Sae-Tia S, Fries BC. 2020. Candidiasis and Mechanisms of Antifungal Resistance. *Antibiotics (Basel)* 9.
10. Berkow EL, Lockhart SR, Ostrosky-Zeichner L. 2020. Antifungal Susceptibility Testing: Current Approaches. *Clin Microbiol Rev* 33.
11. Arendrup MC, Friberg N, Mares M, Kahlmeter G, Meletiadis J, Guinea J, Subcommittee on Antifungal Susceptibility Testing of the EECfAST. 2020. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). *Clin Microbiol Infect* doi:10.1016/j.cmi.2020.06.007.

12. Borman AM, Muller J, Walsh-Quantick J, Szekely A, Patterson Z, Palmer MD, Fraser M, Johnson EM. 2020. MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method. *J Antimicrob Chemother* 75:1194-1205.
13. Diaz-Garcia J, Alcala L, Martin-Rabadan P, Mesquida A, Sanchez-Carrillo C, Reigadas E, Munoz P, Escribano P, Guinea J. 2019. Susceptibility of uncommon *Candida* species to systemic antifungals by the EUCAST methodology. *Med Mycol* doi:10.1093/mmy/myz121.
14. Guinea J, Zaragoza O, Escribano P, Martin-Mazuelos E, Peman J, Sanchez-Reus F, Cuenca-Estrella M, Candipop Project G-G, Reipi. 2014. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. *Antimicrob Agents Chemother* 58:1529-37.
15. Jung IY, Jeong SJ, Kim YK, Kim HY, Song YG, Kim JM, Choi JY. 2020. A multicenter retrospective analysis of the antifungal susceptibility patterns of *Candida* species and the predictive factors of mortality in South Korean patients with candidemia. *Medicine (Baltimore)* 99:e19494.
16. Pfaller MA, Castanheira M, Messer SA, Jones RN. 2015. In vitro antifungal susceptibilities of isolates of *Candida* spp. and *Aspergillus* spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. *Mycoses* 58:209-14.
17. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. 2019. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for *Candida* Species From 1997-2016. *Open Forum Infect Dis* 6:S79-S94.
18. Pfaller MA, Messer SA, Jones RN, Castanheira M. 2015. Antifungal susceptibilities of *Candida*, *Cryptococcus neoformans* and *Aspergillus fumigatus* from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). *J Antibiot (Tokyo)* 68:556-61.

19. Xiao M, Chen SC, Kong F, Xu XL, Yan L, Kong HS, Fan X, Hou X, Cheng JW, Zhou ML, Li Y, Yu SY, Huang JJ, Zhang G, Yang Y, Zhang JJ, Duan SM, Kang W, Wang H, Xu YC. 2020. Distribution and Antifungal Susceptibility of *Candida* Species Causing Candidemia in China: An Update From the CHIF-NET Study. *J Infect Dis* 221:S139-S147.
20. Xiao M, Sun ZY, Kang M, Guo DW, Liao K, Chen SC, Kong F, Fan X, Cheng JW, Hou X, Zhou ML, Li Y, Yu SY, Huang JJ, Wang H, Xu YC, China Hospital Invasive Fungal Surveillance Net Study G. 2018. Five-Year National Surveillance of Invasive Candidiasis: Species Distribution and Azole Susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. *J Clin Microbiol* 56.
21. Astvad KMT, Hare RK, Arendrup MC. 2017. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical *Candida* and *Aspergillus* isolates. *Clin Microbiol Infect* 23:882-887.
22. Perez-Hansen A, Lass-Flörl C, Lackner M, Rare Yeast Study G. 2019. Antifungal susceptibility profiles of rare ascomycetous yeasts. *J Antimicrob Chemother* 74:2649-2656.
23. Xiao M, Chen SC, Kong F, Fan X, Cheng JW, Hou X, Zhou ML, Wang H, Xu YC, China Hospital Invasive Fungal Surveillance Net Study G. 2018. Five-year China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study of invasive fungal infections caused by noncandidal yeasts: species distribution and azole susceptibility. *Infect Drug Resist* 11:1659-1667.
24. Jamiu AT, Albertyn J, Sebolai OM, Pohl CH. 2020. Update on *Candida krusei*, a potential multidrug-resistant pathogen. *Med Mycol* doi:10.1093/mmy/myaa031.
25. Bretagne S, Renaudat C, Desnos-Ollivier M, Sitbon K, Lortholary O, Dromer F, French Mycosis Study G. 2017. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002-14). *J Antimicrob Chemother* 72:1784-1793.
26. Desnos-Ollivier M, Robert V, Raoux-Barbot D, Groenewald M, Dromer F. 2012. Antifungal susceptibility profiles of 1698 yeast reference strains revealing potential emerging human pathogens. *PLoS One* 7:e32278.

- 428 27. Fernandez-Ruiz M, Guinea J, Puig-Asensio M, Zaragoza O, Almirante B, Cuenca-Estrella M,
429 Aguado JM, Project C, Geih G, Reipi. 2017. Fungemia due to rare opportunistic yeasts: data
430 from a population-based surveillance in Spain. *Med Mycol* 55:125-136.
- 431 28. Borman AM, Muller J, Walsh-Quantick J, Szekely A, Patterson Z, Palmer MD, Fraser M,
432 Johnson EM. 2019. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast
433 Species from the United Kingdom. *Antimicrob Agents Chemother* 63.
- 434 29. Canton E, Peman J, Quindos G, Eraso E, Miranda-Zapico I, Alvarez M, Merino P, Campos-
435 Herrero I, Marco F, de la Pedrosa EG, Yague G, Guna R, Rubio C, Miranda C, Pazos C,
436 Velasco D, Group FS. 2011. Prospective multicenter study of the epidemiology, molecular
437 identification, and antifungal susceptibility of *Candida parapsilosis*, *Candida orthopsilosis*,
438 and *Candida metapsilosis* isolated from patients with candidemia. *Antimicrob Agents*
439 *Chemother* 55:5590-6.
- 440 30. Gago S, Garcia-Rodas R, Cuesta I, Mellado E, Alastruey-Izquierdo A. 2014. *Candida*
441 *parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis* virulence in the non-
442 conventional host *Galleria mellonella*. *Virulence* 5:278-85.
- 443 31. Al-Obaid K, Ahmad S, Joseph L, Khan Z. 2018. *Lodderomyces elongisporus*: a bloodstream
444 pathogen of greater clinical significance. *New Microbes New Infect* 26:20-24.
- 445 32. Al-Sweih N, Ahmad S, Khan S, Joseph L, Asadzadeh M, Khan Z. 2019. *Cyberlindnera*
446 *fabianii* fungaemia outbreak in preterm neonates in Kuwait and literature review. *Mycoses*
447 62:51-61.
- 448 33. Bournoux ME, Gueho E, Potocka AC. 1993. Resolutive *Candida utilis* fungemia in a
449 nonneutropenic patient. *J Clin Microbiol* 31:1644-5.
- 450 34. Dutra VR, Silva LF, Oliveira ANM, Beirigo EF, Arthur VM, Bernardes da Silva R, Ferreira
451 TB, Andrade-Silva L, Silva MV, Fonseca FM, Silva-Vergara ML, Ferreira-Paim K. 2020.
452 Fatal Case of Fungemia by *Wickerhamomyces anomalus* in a Pediatric Patient Diagnosed in a
453 Teaching Hospital from Brazil. *J Fungi (Basel)* 6.

35. Jung J, Moon YS, Yoo JA, Lim JH, Jeong J, Jun JB. 2018. Investigation of a nosocomial outbreak of fungemia caused by *Candida pelliculosa* (*Pichia anomala*) in a Korean tertiary care center. *J Microbiol Immunol Infect* 51:794-801.
36. Lin HC, Lin HY, Su BH, Ho MW, Ho CM, Lee CY, Lin MH, Hsieh HY, Lin HC, Li TC, Hwang KP, Lu JJ. 2013. Reporting an outbreak of *Candida pelliculosa* fungemia in a neonatal intensive care unit. *J Microbiol Immunol Infect* 46:456-62.
37. Park JH, Oh J, Sang H, Shrestha B, Lee H, Koo J, Cho SI, Choi JS, Lee MH, Kim J, Sung GH. 2019. Identification and Antifungal Susceptibility Profiles of *Cyberlindnera fabianii* in Korea. *Mycobiology* 47:449-456.
38. Zhou M, Yu S, Kudinha T, Xiao M, Wang H, Xu Y, Zhao H. 2019. Identification and antifungal susceptibility profiles of *Kodamaea ohmeri* based on a seven-year multicenter surveillance study. *Infect Drug Resist* 12:1657-1664.
39. Arastehfar A, Lass-Flörl C, Garcia-Rubio R, Daneshnia F, Ilkit M, Boekhout T, Gabaldon T, Perlin DS. 2020. The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. *J Fungi (Basel)* 6.
40. Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA. 2017. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in *Candida albicans*. *Antimicrob Agents Chemother* 61.
41. Lass-Flörl C, Mayr A, Aigner M, Lackner M, Orth-Holler D. 2018. A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria. *Infection* 46:701-704.
42. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodriguez-Bano J, Group EP-NC-M. 2018. Surveillance for control of antimicrobial resistance. *Lancet Infect Dis* 18:e99-e106.
43. Trouve C, Blot S, Hayette MP, Jonckheere S, Patteet S, Rodriguez-Villalobos H, Symoens F, Van Wijngaerden E, Lagrou K. 2017. Epidemiology and reporting of candidaemia in Belgium: a multi-centre study. *Eur J Clin Microbiol Infect Dis* 36:649-655.

44. Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ, Castanheira M. 2020. Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). *Diagn Microbiol Infect Dis* 97:115016.
45. Lortholary O, Renaudat C, Sitbon K, Desnos-Ollivier M, Bretagne S, Dromer F, French Mycoses Study G. 2017. The risk and clinical outcome of candidemia depending on underlying malignancy. *Intensive Care Med* 43:652-662.
46. Bassetti M, Vena A, Bouza E, Peghin M, Munoz P, Righi E, Pea F, Lackner M, Lass-Flörl C. 2020. Antifungal susceptibility testing in *Candida*, *Aspergillus* and *Cryptococcus* infections: are the MICs useful for clinicians? *Clin Microbiol Infect* 26:1024-1033.
47. Donnelly SM, Sullivan DJ, Shanley DB, Coleman DC. 1999. Phylogenetic analysis and rapid identification of *Candida dubliniensis* based on analysis of ACT1 intron and exon sequences. *Microbiology* 145 1871-82.
48. de Hoog GS, van den Ende GAH. 1998. Molecular diagnostics of clinical strains of filamentous Basidiomycetes. *Mycoses* 41:183-9.
49. Masclaux F, Gueho E, de Hoog GS, Christen R. 1995. Phylogenetic relationships of human-pathogenic *Cladosporium* (*Xylohypha*) species inferred from partial LS rRNA sequences. *J Med Vet Mycol* 33:327-38.
50. O'Donnell K. 1993. *Fusarium* and its near relatives, p 225-233. In Taylor DRRaJW (ed), *The fungal holomorph: mitotic, meiotic and pleomorphic speciation in fungal systematics*, CAB International, Wallingford, United kingdom.
51. Guzman B, Lachance MA, Herrera CM. 2013. Phylogenetic analysis of the angiosperm-floricolous insect-yeast association: have yeast and angiosperm lineages co-diversified? *Mol Phylogenet Evol* 68:161-75.
52. Martorell P, Fernandez-Espinar MT, Querol A. 2005. Sequence-based identification of species belonging to the genus *Debaryomyces*. *FEMS Yeast Res* 5:1157-65.

508 53. Desnos-Ollivier M, Bretagne S, Boullie A, Gautier C, Dromer F, Lortholary O, French
509 Mycoses Study G. 2019. Isavuconazole MIC distribution of 29 yeast species responsible for
510 invasive infections (2015-2017). Clin Microbiol Infect 25:634 e1-634 e4.

511 54. Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. 2002. Sequence analysis of the
512 ribosomal DNA intergenic spacer 1 regions of *Trichosporon* species. J Clin Microbiol
513 40:1826-30.

514 55. Lengeler KB, Cox GM, Heitman J. 2001. Serotype AD strains of *Cryptococcus neoformans*
515 are diploid or aneuploid and are heterozygous at the mating-type locus. Infect Immun 69:115-
516 22.

517